| 28.55 -1.03 (-3.48%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.42 | 1-year : | 41.37 |
| Resists | First : | 30.32 | Second : | 35.42 |
| Pivot price | 28.7  |
|||
| Supports | First : | 24.55 | Second : | 20.98 |
| MAs | MA(5) : | 29.22 |
MA(20) : | 28.29 |
| MA(100) : | 22.76 |
MA(250) : | 16.25 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 71.2 |
D(3) : | 77.7 |
| RSI | RSI(14): 57.5 |
|||
| 52-week | High : | 30.32 | Low : | 8.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ROIV ] has closed above bottom band by 44.9%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.36 - 29.56 | 29.56 - 29.72 |
| Low: | 27.9 - 28.09 | 28.09 - 28.24 |
| Close: | 28.27 - 28.58 | 28.58 - 28.84 |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Wed, 11 Mar 2026
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Tue, 10 Mar 2026
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week High - Here's Why - MarketBeat
Wed, 04 Mar 2026
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Wed, 04 Mar 2026
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Tue, 03 Mar 2026
Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026 - Meyka
Tue, 03 Mar 2026
Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 716 (M) |
| Held by Insiders | 5.2723e+008 (%) |
| Held by Institutions | 22.7 (%) |
| Shares Short | 24,530 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.26e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 965.2 % |
| Return on Equity (ttm) | -14.5 % |
| Qtrly Rev. Growth | 1.331e+007 % |
| Gross Profit (p.s.) | -64.3 |
| Sales Per Share | -15.82 |
| EBITDA (p.s.) | -5.07992e+008 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -759 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.81 |
| Price to Cash Flow | 5.73 |
| Dividend | 0 |
| Forward Dividend | 2.227e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|